Literature DB >> 17382544

Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.

John J M Wiener1, Laurent Gomez, Hariharan Venkatesan, Alejandro Santillán, Brett D Allison, Kimberly L Schwarz, Shirin Shinde, Liu Tang, Michael D Hack, Brian J Morrow, S Timothy Motley, Raul M Goldschmidt, Karen Joy Shaw, Todd K Jones, Cheryl A Grice.   

Abstract

We have previously reported a novel class of tetrahydroindazoles that display potency against a variety of Gram-positive and Gram-negative bacteria, potentially via interaction with type II bacterial topoisomerases. Herein are reported SAR investigations of this new series. Several compounds possessing broad-spectrum potency were prepared. Further, these compounds exhibit activity against multidrug-resistant Gram-positive microorganisms equivalent to that against susceptible strains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17382544     DOI: 10.1016/j.bmcl.2007.03.004

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Type IIA topoisomerase inhibition by a new class of antibacterial agents.

Authors:  Benjamin D Bax; Pan F Chan; Drake S Eggleston; Andrew Fosberry; Daniel R Gentry; Fabrice Gorrec; Ilaria Giordano; Michael M Hann; Alan Hennessy; Martin Hibbs; Jianzhong Huang; Emma Jones; Jo Jones; Kristin Koretke Brown; Ceri J Lewis; Earl W May; Martin R Saunders; Onkar Singh; Claus E Spitzfaden; Carol Shen; Anthony Shillings; Andrew J Theobald; Alexandre Wohlkonig; Neil D Pearson; Michael N Gwynn
Journal:  Nature       Date:  2010-08-04       Impact factor: 49.962

Review 2.  In front of and behind the replication fork: bacterial type IIA topoisomerases.

Authors:  Claudia Sissi; Manlio Palumbo
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 3.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.

Authors:  Christopher M Tan; Charles J Gill; Jin Wu; Nathalie Toussaint; Jingjun Yin; Takayuki Tsuchiya; Charles G Garlisi; David Kaelin; Peter T Meinke; Lynn Miesel; David B Olsen; Armando Lagrutta; Hideyuki Fukuda; Ryuta Kishii; Masaya Takei; Kouhei Oohata; Tomoko Takeuchi; Taku Shibue; Hisashi Takano; Akinori Nishimura; Yasumichi Fukuda; Sheo B Singh
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

5.  Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.

Authors:  Gunther Kern; Tiffany Palmer; David E Ehmann; Adam B Shapiro; Beth Andrews; Gregory S Basarab; Peter Doig; Jun Fan; Ning Gao; Scott D Mills; John Mueller; Shubha Sriram; Jason Thresher; Grant K Walkup
Journal:  J Biol Chem       Date:  2015-07-06       Impact factor: 5.157

6.  Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents.

Authors:  Sheo B Singh; David E Kaelin; Jin Wu; Lynn Miesel; Christopher M Tan; Peter T Meinke; David Olsen; Armando Lagrutta; Prudence Bradley; Jun Lu; Sangita Patel; Keith W Rickert; Robert F Smith; Stephen Soisson; Changqing Wei; Hideyuki Fukuda; Ryuta Kishii; Masaya Takei; Yasumichi Fukuda
Journal:  ACS Med Chem Lett       Date:  2014-03-12       Impact factor: 4.345

7.  N-Benzyl-3-sulfonamidopyrrolidines are a New Class of Bacterial DNA Gyrase Inhibitors.

Authors:  Marie H Foss; Katherine A Hurley; Nohemy Sorto; Laura L Lackner; Kelsey M Thornton; Jared T Shaw; Douglas B Weibel
Journal:  ACS Med Chem Lett       Date:  2011-04-14       Impact factor: 4.345

Review 8.  Exploiting bacterial DNA gyrase as a drug target: current state and perspectives.

Authors:  Frédéric Collin; Shantanu Karkare; Anthony Maxwell
Journal:  Appl Microbiol Biotechnol       Date:  2011-09-09       Impact factor: 4.813

Review 9.  Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target.

Authors:  Andrew Robinson; Rebecca J Causer; Nicholas E Dixon
Journal:  Curr Drug Targets       Date:  2012-03       Impact factor: 3.465

10.  Crystal structure of 3,6,6-trimethyl-4-oxo-1-(pyridin-2-yl)-4,5,6,7-tetra-hydro-1H-indazol-7-aminium chloride and its monohydrate.

Authors:  Anatoly Mishnev; Alvis Mengots; Māris Turks
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.